---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-133757"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T14:54:06.670826+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Veru reports Q2 fiscal 2024 net loss $10M, cash $34.7M; enobosarm Phase 2b enrolling

## Summary
- Fiscal Q2 net revenues $4.1M (down 38% YoY); net loss $10.0M ($0.07/share) vs $33.8M loss ($0.42) prior year.
- Cash and equivalents $34.7M at March 31, 2024, up from $9.6M at Sept 30, 2023.
- Phase 2b enobosarm+semaglutide weight loss trial actively enrolling; topline results expected end of 2024.
- Extension trial to test muscle maintenance after GLP-1 discontinuation; results expected Q2 2025.
- Assembled five-MD Scientific Advisory Board for high quality weight loss program.

## SEC filing metadata
- accession: 0001193125-24-133757
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312524133757/0001193125-24-133757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312524133757/d820381d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-133757
- JSON: https://secwatch.observer/filing/0001193125-24-133757.json
- Plain text: https://secwatch.observer/filing/0001193125-24-133757.txt

## Key facts
- Earnings Releases
  VERU INC. reported the quarter and six months ended March 31, 2024 results: revenue $4.1 million, net income $10.0 million, or $0.07 per share, EPS $0.07 per share.
  - Period: the quarter and six months ended March 31, 2024
  - Revenue: $4.1 million
  - Net income: $10.0 million, or $0.07 per share
  - EPS: $0.07 per share
  - Result: reported results
  source text: the separate blinded Phase 2b extension clinical study are expected in calendar Q2 2025. Second Quarter Financial Summary: Fiscal 2024 vs Fiscal 2023 • Net revenues decreased to $4.1 million from $6.6 million • Gross profit decreased to $0.7 million from $4.1 million • Research and development expenses decreased to $3.0 million from $17.9 million, as restated •
  evidence_url: https://www.sec.gov/Archives/edgar/data/863894/000119312524133757/0001193125-24-133757-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.